Optimizing the aryl-triazole of cjoc42 for enhanced gankyrin binding and anti-cancer activity

Gankyrin is an oncoprotein overexpressed in numerous cancer types and appears to play a key role in regulating cell proliferation, cell growth, and cell migration. These roles are largely due to gankyrin's protein-protein interaction with the 26S proteasome. We previously published a study exploring the aryl sulfonate ester of cjoc42 in an effort to enhance gankyrin binding and inhibit cancer cell proliferation. In order to further improve the gankyrin binding ability of the cjoc42 scaffold, an extensive SAR for the aryl-triazole moiety of cjoc42 was developed. Our cjoc42 derivatives exhibited enhanced gankyrin binding, as well as enhanced antiproliferative activity against Hep3B, HepG2, A549, and MDA-MB-231 cancer cell lines.

Same day/next day discharge of burn patients treated with skin grafts

In the past, many patients were admitted for a minimum of 72 h for split-thickness skin grafting (STSG). Several factors have caused us to discharge burn patients on the same day or within 24 h following STSG. We have reviewed outcomes of such patients to determine whether early discharge has an adverse effect on graft outcome and to determine patient acceptance of this new procedure. We retrospectively reviewed charts of patients consecutively treated at our hospital. Two hundred patients were identified. All patients were found to have successful grafts. From our results, we can conclude that patient discharge in less than 24 h following STSG does not predispose patients to poor graft take or other adverse outcomes.